Imaging for the pretreatment staging of small cell lung cancer
Treadwell JR, Mitchell MD, Tsou A, Torigian DA, Aggarwal C, Schoelles KM
Record ID 32016000650
English
Authors' objectives:
For small cell lung cancer (SCLC), several imaging modalities can be used to determine cancer staging, which is important to ensure optimal management. Our aim was to synthesize the literature on whether some imaging modalities are better than others for the pretreatment staging of small cell lung cancer. We searched for evidence on comparative accuracy (sensitivity, specificity) as well as subsequent clinical outcomes (choice of treatment, survival, and quality of life).
Authors' recommendations:
Evidence is sparse on imaging modalities in the pretreatment staging of small cell lung cancer. Nevertheless, we drew three conclusions about comparative accuracy: (1) FDG PET/CT is more sensitive than MDCT for detecting osseous metastases; (2) FDG PET/CT is more sensitive than bone scintigraphy for detecting osseous metastases; (3) Standard staging plus FDG PET/CT is more sensitive than standard staging alone for detecting any distant metastases. We assigned a grade of low to the strength of evidence for these conclusions, mostly due to risk of bias and a small number of studies. Research gaps include the dearth of evidence on several tests of interest (particularly MRI, EBUS, EUS, and PET/MRI), a lack of study designs to
compare tests on patient-oriented outcomes such as survival, and a lack of data on whether comparative accuracy or effectiveness are associated with patient factors.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
https://www.effectivehealthcare.ahrq.gov/ehc/products/595/2211/lung-cancer-staging-report-160414.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Diagnostic Imaging
- Lung Neoplasms
- Small Cell Lung Carcinoma
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.